Patents by Inventor Francois Maltais

Francois Maltais has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE
    Publication number: 20110135603
    Abstract: The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3K?. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Application
    Filed: October 15, 2010
    Publication date: June 9, 2011
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Tiansheng Wang, Alexander Aronov, Mark Cornebise, Francois Maltais, Mark Ledeboer, Arnaud Le Tiran, Valerie Marone, David Messesrsmith, Kevin Cottrell, Jon H. Come, Gabriel Martinez Botella
  • Inhibitors of aspartyl protease
    Patent number: 7919523
    Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
    Type: Grant
    Filed: July 2, 2008
    Date of Patent: April 5, 2011
    Assignee: Vertex Pharmaceuticals, Inc.
    Inventors: Michael R. Hale, Christopher T. Baker, Timothy A. Stammers, Ronald George Sherrill, Andrew Spaltenstein, Eric Steven Furfine, Francois Maltais, Clarence Webster Andrews, III, John Franklin Miller, Vicente Samano
  • KINASE INHIBITORS
    Publication number: 20110077237
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.
    Type: Application
    Filed: April 1, 2010
    Publication date: March 31, 2011
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Juan-Miguel Jimenez, Guy W. Bemis, Francois Maltais, Tiansheng Wang, Ronald Knegtel, Chris Davis, Damien Fraysse, Dean Boyall, Luca Settimo, Stephen Young, Michael Mortimore
  • DEUTERATED HEPATITIS C PROTEASE INHIBITORS
    Publication number: 20110071074
    Abstract: A deuterated ?-ketoamido steric specific compound of the formula wherein D denotes a deuterium atom on a steric specific carbon atom.
    Type: Application
    Filed: November 24, 2010
    Publication date: March 24, 2011
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Robert B. Perni, Youssef Bennani, Gregor Zlokarnik, Gerald J. Tanoury, Minzhang Chen, Young Chun Jung, Raymond E. Forslund, Francois Maltais
  • Ion channel modulators and methods of use
    Patent number: 7767680
    Abstract: In general, the invention relates to novel 4-phenylpyrimidine compounds useful as ion channel modulators. It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are useful as inhibitors of voltage-gated sodium channels and/or calcium channels.
    Type: Grant
    Filed: November 3, 2005
    Date of Patent: August 3, 2010
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Esther Martinborough, Nicole Zimmermann, Robert B. Perni, Michael Arnost, Upul K. Bandarage, Francois Maltais, Guy Bemis
  • Ion Channel Modulators and Methods of Uses
    Publication number: 20100184753
    Abstract: In general, the invention relates to compounds useful as ion channel modulators. It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are useful as inhibitors of voltage-gated sodium channels and/or calcium channels.
    Type: Application
    Filed: March 15, 2010
    Publication date: July 22, 2010
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Esther Martinborough, Nicole Zimmermann, Robert B. Perni, Michael Arnost, Upul Bandarage, Francois Maltais, Guy Bemis
  • INHIBITORS OF C-MET AND USES THEREOF
    Publication number: 20100144721
    Abstract: The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3K?. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Application
    Filed: September 4, 2007
    Publication date: June 10, 2010
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Tiansheng Wang, Jeremy Green, Brain Ledford, Francois Maltais, Andreas Termin
  • DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES
    Publication number: 20090227607
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Application
    Filed: October 3, 2008
    Publication date: September 10, 2009
    Inventors: Mark Ledeboer, David Messersmith, Francois Maltais, Huai Gao, Tiansheng Wang, Jingrong Cao, John Duffy, Gabriel Martinez-Botella, Cornelia Forster, Marion Wannamaker, Francesco Salituro, Albert Pierce, Luc Farmer, Valerie Marone
  • KINASE INHIBITORS
    Publication number: 20090124602
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.
    Type: Application
    Filed: August 7, 2008
    Publication date: May 14, 2009
    Inventors: FRANCOIS MALTAIS, GUY BEMIS, TIANSHENG WANG, JUAN-MIGUEL JIMENEZ, RONALD KNEGTEL, CHRIS DAVIS, DAMIEN FRAYSSE
  • Deazapurines useful as inhibitors of Janus kinases
    Publication number: 20090088445
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Application
    Filed: April 5, 2007
    Publication date: April 2, 2009
    Inventors: Mark Ledeboer, David Messersmith, Francois Maltais, Huai Gao, Tiansheng Wang, Jingrong Cao, John Duffy, Gabriel Martinez-Botella, Cornelia Forster, Marion Wannamaker, Francesco Salituro, Albert Pierce, Luc Farmer, Valerie Marone
  • Selective inhibitors of ERK protein kinase and uses thereof
    Patent number: 7501415
    Abstract: Described herein are compounds that are useful as ERK2 inhibitors. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including proliferative disorders such as cancer.
    Type: Grant
    Filed: December 20, 2005
    Date of Patent: March 10, 2009
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Alexander Aronov, Michael Hale, Francois Maltais, Gabriel Martinez-Botella, Judith Straub, Qing Tang
  • Inhibitors of aspartyl protease
    Publication number: 20090042973
    Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
    Type: Application
    Filed: July 2, 2008
    Publication date: February 12, 2009
    Inventors: Michael R. Hale, Christopher T. Baker, Timothy A. Stammers, Ronald George Sherrill, Andrew Spaltenstein, Eric Steven Furfine, Francois Maltais, Clarence Webster Andrews, III, John Franklin Miller, Vicente Samano
  • Compositions useful as protein kinase inhibitors
    Patent number: 7456190
    Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Grant
    Filed: March 11, 2004
    Date of Patent: November 25, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Francois Maltais, Alex Aronov, Michael R. Hale, Young-Choon Moon
  • Inhibitors of aspartyl protease
    Patent number: 7442718
    Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
    Type: Grant
    Filed: July 2, 2003
    Date of Patent: October 28, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Michael R Hale, Christopher T Baker, Timothy A Stammers, Ronald G Sherrill, Andrew Spaltenstein, Eric S Furfine, Francois Maltais, Clarence W Andrews, III, John F Miller, Vicente Samano
  • Heteroaryl compounds useful as inhibitors or protein kinases
    Patent number: 7407962
    Abstract: The present invention provides compounds that are inhibitors of protein kinase, particularly inhibitors of ERK2, GSK3, PKA, CDK2 protein kinases, mammalian protein kinases involved in proliferative and neurodegenerative disorders. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of utilizing those compositions in the treatment of various disorders.
    Type: Grant
    Filed: February 3, 2004
    Date of Patent: August 5, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Alex Aronov, Michael R. Hale, Francois Maltais, Qing Tang
  • Prodrugs of an ERK protein kinase inhibitor
    Patent number: 7358258
    Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Grant
    Filed: May 13, 2005
    Date of Patent: April 15, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Michael Robin Hale, Francois Maltais, Gabriel Martinez-Botella, Judith Straub, Qing Tang
  • Isoxazole compositions useful as inhibitors of ERK
    Patent number: 7354919
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors, especially inhibitors of ERK, having the formula: where A, B, R1, R2, T and Ht are described in the specification. The compounds are useful for treating diseases in mammals that are alleviated by a protein, kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.
    Type: Grant
    Filed: July 24, 2003
    Date of Patent: April 8, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Michael R. Hale, James W. Janetka, Francois Maltais, Jingrong Cao
  • Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto
    Patent number: 7354939
    Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Grant
    Filed: May 13, 2005
    Date of Patent: April 8, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Gabriel Martinez-Botella, Michael Hale, Francois Maltais, Judith Straub, Qing Tang
  • Heterocyclic inhibitors of ERK2 and uses thereof
    Patent number: 7345054
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: wherein A1, A2, TmR1, X, R2, R3, R9, R12, and R13 are as described in the specification. The compounds are especially useful as inhibitors of ERK2, Aurora2, GSK3, CDK2, AKT3, and ROCK protein kinases and for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, neurodegenerative disorders, inflammatory disorders, restenosis, diabetes, and cardiovascular disease.
    Type: Grant
    Filed: March 10, 2005
    Date of Patent: March 18, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Michael Robin Hale, Francois Maltais, Qing Tang, Judith Straub, Alexander Aronov
  • Heterocyclic inhibitors of ERK2 and uses thereof
    Patent number: 7304061
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: wherein A1, A2, TmR1, X, R2, R3, R9, R12, and R13 are as described in the specification. The compounds are especially useful as inhibitors of ERK2, Aurora2, GSK3, CDK2, AKT3, and ROCK protein kinases and for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, neurodegenerative disorders, inflammatory disorders, restenosis, diabetes, and cardiovascular disease.
    Type: Grant
    Filed: April 25, 2003
    Date of Patent: December 4, 2007
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Michael Robin Hale, Francois Maltais, Qing Tang, Judith Straub, Alexander Aronov